^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Interferon γ (IFN-γ) gene signature and tryptophan 2,3-dioxygenase 2 (TDO2) gene expression: a potential predictive composite biomarker for linrodostat mesylate (BMS-986205; indoleamine 2,3-dioxygenase 1 inhibitor [IDO1i]) + nivolumab (NIVO)

Published date:
09/28/2019
Excerpt:
Tumor and serum samples were obtained from pts with solid tumors (bladder, cervical, melanoma, lung, pancreatic, renal cell, head and neck) and lymphoma treated with linrodostat + NIVO during the expansion phase in CA017-003....high IFN-γ gene signature (Ayers et al. J Clin Invest. 2017) was associated with response and improved progression-free and overall survival....IFN-ɣ signature and TDO2 gene expression may be a potential composite biomarker to identify pts with certain tumor types more likely to respond to linrodostat mesylate + NIVO.
DOI:
10.1093/annonc/mdz268
Trial ID: